Baseline patient and disease characteristics
| Characteristic . | G-CHOP 400/400 mg (n = 14) . | G-CHOP 1600/800 mg (n = 14) . | G-CHOP total (n = 28) . | G-FC 400/400 mg (n = 14) . | G-FC 1600/800 mg (n = 14) . | G-FC total (n = 28) . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | |
| Age, y | ||||||||||||
| Median | 61.0 | 66.0 | 62.5 | 61.5 | 60.5 | 61.0 | ||||||
| Range | 32-75 | 34-75 | 32-75 | 48-77 | 45-77 | 45-77 | ||||||
| Male | 5 | 36 | 6 | 43 | 11 | 39 | 7 | 50 | 10 | 71 | 17 | 61 |
| Ann Arbor stage at study entry | ||||||||||||
| I-II | 3 | 21 | 6 | 43 | 9 | 32 | 4 | 29 | 1 | 7 | 5 | 18 |
| III-IV | 11 | 79 | 8 | 57 | 19 | 68 | 10 | 71 | 13 | 93 | 23 | 82 |
| Bulky disease (≥7 cm) | 7 | 50 | 2 | 14 | 9 | 32 | 1 | 7 | 4 | 29 | 5 | 18 |
| No. of patients with bone marrow involvement of total No. of patients in subgroup | 5/14 | 36 | 2/14 | 14 | 7/28 | 25 | 2/13 | 15 | 5/14 | 36 | 7/27 | 26 |
| FLIPI score at study entry | ||||||||||||
| Low (0-1) | 5 | 36 | 3 | 21 | 8 | 29 | 5 | 36 | 3 | 21 | 8 | 29 |
| Intermediate (2) | 5 | 36 | 9 | 64 | 14 | 50 | 4 | 29 | 5 | 36 | 9 | 32 |
| High (3-5) | 4 | 29 | 2 | 14 | 6 | 21 | 5 | 36 | 6 | 43 | 11 | 39 |
| Time from first diagnosis, months | ||||||||||||
| Median | 38 | 34 | 36 | 51 | 49 | 51 | ||||||
| Range | 19-229 | 7-88 | 7-229 | 14-181 | 19-305 | 14-305 | ||||||
| No. of prior treatment lines | ||||||||||||
| Median | 1 | 1 | 1 | 2 | 2 | 2 | ||||||
| Range | 1-3 | 1-2 | 1-3 | 1-4 | 1-6 | 1-6 | ||||||
| Refractory to last treatment | 1 | 7 | 4 | 29 | 5 | 18 | 2 | 14 | 5 | 36 | 7 | 25 |
| No. of prior rituximab treatment lines | ||||||||||||
| Median | 1 | 1 | 1 | 1 | 1.5 | 1 | ||||||
| Range | 1-2 | 1-2 | 1-2 | 1-2 | 0-3 | 0-3 | ||||||
| Rituximab refractory | 1 | 7 | 3 | 21 | 4 | 14 | 4 | 29 | 6 | 43 | 10 | 36 |
| Characteristic . | G-CHOP 400/400 mg (n = 14) . | G-CHOP 1600/800 mg (n = 14) . | G-CHOP total (n = 28) . | G-FC 400/400 mg (n = 14) . | G-FC 1600/800 mg (n = 14) . | G-FC total (n = 28) . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | |
| Age, y | ||||||||||||
| Median | 61.0 | 66.0 | 62.5 | 61.5 | 60.5 | 61.0 | ||||||
| Range | 32-75 | 34-75 | 32-75 | 48-77 | 45-77 | 45-77 | ||||||
| Male | 5 | 36 | 6 | 43 | 11 | 39 | 7 | 50 | 10 | 71 | 17 | 61 |
| Ann Arbor stage at study entry | ||||||||||||
| I-II | 3 | 21 | 6 | 43 | 9 | 32 | 4 | 29 | 1 | 7 | 5 | 18 |
| III-IV | 11 | 79 | 8 | 57 | 19 | 68 | 10 | 71 | 13 | 93 | 23 | 82 |
| Bulky disease (≥7 cm) | 7 | 50 | 2 | 14 | 9 | 32 | 1 | 7 | 4 | 29 | 5 | 18 |
| No. of patients with bone marrow involvement of total No. of patients in subgroup | 5/14 | 36 | 2/14 | 14 | 7/28 | 25 | 2/13 | 15 | 5/14 | 36 | 7/27 | 26 |
| FLIPI score at study entry | ||||||||||||
| Low (0-1) | 5 | 36 | 3 | 21 | 8 | 29 | 5 | 36 | 3 | 21 | 8 | 29 |
| Intermediate (2) | 5 | 36 | 9 | 64 | 14 | 50 | 4 | 29 | 5 | 36 | 9 | 32 |
| High (3-5) | 4 | 29 | 2 | 14 | 6 | 21 | 5 | 36 | 6 | 43 | 11 | 39 |
| Time from first diagnosis, months | ||||||||||||
| Median | 38 | 34 | 36 | 51 | 49 | 51 | ||||||
| Range | 19-229 | 7-88 | 7-229 | 14-181 | 19-305 | 14-305 | ||||||
| No. of prior treatment lines | ||||||||||||
| Median | 1 | 1 | 1 | 2 | 2 | 2 | ||||||
| Range | 1-3 | 1-2 | 1-3 | 1-4 | 1-6 | 1-6 | ||||||
| Refractory to last treatment | 1 | 7 | 4 | 29 | 5 | 18 | 2 | 14 | 5 | 36 | 7 | 25 |
| No. of prior rituximab treatment lines | ||||||||||||
| Median | 1 | 1 | 1 | 1 | 1.5 | 1 | ||||||
| Range | 1-2 | 1-2 | 1-2 | 1-2 | 0-3 | 0-3 | ||||||
| Rituximab refractory | 1 | 7 | 3 | 21 | 4 | 14 | 4 | 29 | 6 | 43 | 10 | 36 |
FLIPI, Follicular Lymphoma International Prognostic Index.